WHAT'S TRENDING

5 most popular innovation stories in Houston this week

Houston research news dominates this week's top stories. Getty Images

Editor's note: A huge part of innovating new technologies and inventions is research. This week's top stories on InnovationMap was well represented by research happening across sectors — from a map of communities most at-risk for COVID-19 to smart technology for senior living.

3 Houston innovators to know this week

This week's Houston innovators to know includes Aleece Hobson of HX Venture Fund, Leland Putterman of Trivie, and Eleonore Cluzel of gBETA Houston. Photos courtesy

This week's roundup of who's who in Houston innovation include the HX Venture Fund's newest team member, a startup founder whose app is gamifying corporate training, and a Houston accelerator leader who's pivoted to digital. Read more.

Houston expert shares why prototyping is so important to startups

Making a product that is worth further investing in, one that customers will want to buy, requires several prototypes, sometimes tens of prototypes to prove the concept and perfect your idea. Photo courtesy of OKGlobal

Rarely in life is anything perfect on the first attempt. Writers write drafts that are proofed and edited. Musicians practice over and over, and athletes train for years to perfect their skills before becoming pros. So, it only makes sense that a product developer would develop a prototype before manufacturing their products.

But why? Why can't a perfectly designed product go straight from CAD to production? In reality, making a product that is worth further investing in, one that customers will want to buy, requires several prototypes, sometimes tens of prototypes to prove the concept and perfect your idea. Success comes through practice, just like with the musicians and the athletes. Read more.

Here are 3 research projects to watch in Houston

From CBD treatment for man's best friend to smart tech for senior living, here are three research projects coming out of the Bayou City. Getty Images

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston.

In InnovationMap's latest roundup of research projects, we look into studies on traffic-reducing technology, recently funded projects on senior living devices, and the effect of CBD oil on four-legged arthritis patients. Read more.

Texas researchers map out parts of Houston most vulnerable to COVID-19

The most at-risk areas, the study found, are in poorer industrial parts of Houston. Getty Images

A group of researchers from the University of Texas and the University of Houston have created a mapping tool for identifying which parts of the greater Houston area are at the greatest risk from COVID-19.

"The map offers a comparative look at vulnerabilities across Harris County, and could help policy makers determine how to allocate coronavirus tests and health and safety resources," says Amin Kiaghadi, a research associate at UT's Oden Institute for Computational Engineering & Sciences and postdoctoral fellow at the University of Houston, in a news release. Read more.

University of Houston scores spot on top schools in the world for new patents

UH has been ranked among the top schools for new patents. Photo courtesy of University of Houston

A Houston school has ranked on a global list that recognizes new utility patents issued. University of Houston tied for No. 75 on the list with 39 utility patents issued in 2019.

The list is created by the National Academy of Inventors and the Intellectual Property Owners Association based on data from the U.S. Patent and Trademark Office. UH has made the list every year for the past five years.

"The rankings show that UH continues to make a major contribution to the innovation enterprise on the U.S. and global stage," says Amr Elnashai, vice president/vice chancellor for research and technology transfer at UH. Read more.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News